The independent platform for news, articles and advice for professionals in laboratory medicine

CardioRenal receives FDA Breakthrough Device Designation for TENOR

CardioRenal, a pioneer in the remote treatment of patients with severe chronic kidney disease (CKD), has announced that its TENOR device has obtained Breakthrough Device Designation from the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA).

CardioRenal developed TENOR, a connected medical device that combines multiple innovative technologies to assist patients with chronic illnesses, including CKD, in measuring their blood potassium levels at home. Patients will collect blood for testing at home using Tasso+, a convenient, easy-to-use, virtually pain-free blood collection device with FDA 510(k) Class II medical device clearance. Doctors can then remotely access the measured data, enabling them to effectively control and normalise patient potassium levels.

“This designation is a tremendous recognition by the FDA of our R&D excellence. It will boost our efforts in bringing the TENOR device to the millions of patients who need it,” said Maurice Bérenger, CEO of CardioRenal. “We look forward to working closely with the FDA to start our clinical trials later this year.”

To qualify for this status, the equipment must feature breakthrough technologies, there must be no FDA-approved or cleared alternatives to the device, it must have significant advantages over existing approved or cleared alternatives, or its application must serve the best interests of patients.

“People are increasingly calling for at-home health solutions, and the partnership with CardioRenal is an exciting opportunity to again demonstrate the benefits to patient care,” said Ben Casavant, PhD, CEO and co-founder of Tasso, Inc., which makes the Tasso+ device. “We look forward to demonstrating that our blood collection device can be used in combination with the TENOR system to obtain a blood sample in a way that is convenient, addresses patient needs and meets FDA standards for potassium analysis. This fits perfectly in our mission to combine clinical excellence and patient-centric solutions.”

The FDA Breakthrough Devices Program helps patients receive timely access to innovative technologies that have the potential to provide more effective diagnosis or treatment for life-threatening or irreversibly debilitating diseases and conditions. As part of this program, the FDA will provide CardioRenal with priority review and interactive communication from its experts and senior managers, to assist the company on its path to commercialisation in the US.

Globally, around 843 million people live with CKD. These patients frequently have fluctuating blood potassium levels, which exposes them to possible cardiac complications. These associated cardiovascular events account for up to 30% of deaths in patients with CKD.

 

Upcoming Events

Pathology Horizons 2024

MacDonald Bath Spa Hotel, Bath
18-20 April, 2024

Diagnostics North East Conference 2024

The Catalyst, Newcastle upon Tyne
19 April, 2024

ECCMID 2024 - European Congress of Clinical Microbiology and Infectious Diseases

Fira Gran Via, 08038 Barcelona, Spain
27-30 April 2024

British Society for Microbial Technology Annual Microbiology Conference

UK Health Security Agency, Colindale, London
2 May 2024

EQA Reports: Interpreting Key Information & Troubleshooting Tips

ONLINE - Zoom
Thursday 16th May 2024

Participants’ Meeting: UK NEQAS Immunology, Immunochemistry & Allergy

Sheffield Hallam University, City Campus, Howard Street, Sheffield
24th May 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Upcoming Events

Pathology Horizons 2024

MacDonald Bath Spa Hotel, Bath
18-20 April, 2024

Diagnostics North East Conference 2024

The Catalyst, Newcastle upon Tyne
19 April, 2024

ECCMID 2024 - European Congress of Clinical Microbiology and Infectious Diseases

Fira Gran Via, 08038 Barcelona, Spain
27-30 April 2024

British Society for Microbial Technology Annual Microbiology Conference

UK Health Security Agency, Colindale, London
2 May 2024

EQA Reports: Interpreting Key Information & Troubleshooting Tips

ONLINE - Zoom
Thursday 16th May 2024

Participants’ Meeting: UK NEQAS Immunology, Immunochemistry & Allergy

Sheffield Hallam University, City Campus, Howard Street, Sheffield
24th May 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Step Communications Ltd, Step House, North Farm Road, Tunbridge Wells, Kent TN2 3DR
Tel: 01892 779999
www.step-communications.com
© 2024 Step Communications Ltd. Registered in England. Registration Number 3893025